NEW HAVEN, Conn.--CuraGen recently announced a product discovery and pharmacogenomics agreement with COR Therapeutics. CuraGen said it will apply its SeqCalling, GeneCalling, and PathCalling technologies; related services; and pharmacogenomics expertise to identify new drug targets and develop new cardiovascular drugs.
CuraGen retains the rights to newly discovered protein therapeutics for use in the company's internal drug development programs, while COR retains the rights to small-molecule and inhibitory antibody therapeutics generated from the arrangement. The renewable collaboration is valued at about $2.6 million for an initial period of 18 months. CuraGen may also receive milestone and royalty payments for products developed by COR resulting from the cooperation.
CuraGen is "successfully applying" its genomics knowledge to assist collaborators in the pharmaceutical, agricultural, and biotechnology fields, said Jonathan Rothberg, chairman and CEO of CuraGen.